LS Investment Advisors LLC lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 14.7% in the 4th quarter, HoldingsChannel reports. The fund owned 2,457 shares of the life sciences company’s stock after selling 424 shares during the quarter. LS Investment Advisors LLC’s holdings in Illumina were worth $737,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc boosted its stake in shares of Illumina by 1.8% in the 3rd quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock valued at $3,976,649,000 after purchasing an additional 188,516 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Illumina by 12.3% in the 3rd quarter. Jennison Associates LLC now owns 4,826,216 shares of the life sciences company’s stock valued at $1,771,511,000 after purchasing an additional 528,635 shares during the last quarter. Capital International Investors bought a new position in shares of Illumina in the 3rd quarter valued at about $1,482,837,000. Jackson Square Partners LLC boosted its stake in shares of Illumina by 7.7% in the 3rd quarter. Jackson Square Partners LLC now owns 1,429,221 shares of the life sciences company’s stock valued at $524,609,000 after purchasing an additional 102,639 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of Illumina by 272.2% in the 3rd quarter. Canada Pension Plan Investment Board now owns 1,023,452 shares of the life sciences company’s stock valued at $375,668,000 after purchasing an additional 748,500 shares during the last quarter. Hedge funds and other institutional investors own 88.94% of the company’s stock.
Illumina stock opened at $284.10 on Friday. Illumina, Inc. has a fifty-two week low of $210.08 and a fifty-two week high of $372.61. The company has a market cap of $41.76 billion, a P/E ratio of 49.67, a PEG ratio of 2.03 and a beta of 1.20. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.24 and a current ratio of 2.49.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 29th. The life sciences company reported $1.32 EPS for the quarter, missing the consensus estimate of $1.36 by ($0.04). The company had revenue of $867.00 million for the quarter, compared to analyst estimates of $865.33 million. Illumina had a return on equity of 24.51% and a net margin of 24.79%. The business’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the business posted $1.44 earnings per share. Analysts expect that Illumina, Inc. will post 6.51 EPS for the current fiscal year.
Several research analysts have recently issued reports on the stock. Bank of America reaffirmed a “buy” rating and issued a $355.00 target price on shares of Illumina in a research note on Wednesday, January 30th. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Wednesday, January 30th. Leerink Swann raised shares of Illumina to an “outperform” rating and reduced their price objective for the stock from $380.00 to $365.00 in a research note on Wednesday, January 30th. BidaskClub lowered shares of Illumina from a “hold” rating to a “sell” rating in a research note on Tuesday, January 29th. Finally, Deutsche Bank lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 price objective on the stock. in a research note on Friday, January 25th. One research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company. Illumina has a consensus rating of “Buy” and an average target price of $346.40.
In other Illumina news, SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, November 12th. The shares were sold at an average price of $314.63, for a total transaction of $3,146,300.00. Following the sale, the senior vice president now directly owns 79,612 shares in the company, valued at approximately $25,048,323.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction that occurred on Wednesday, December 26th. The stock was sold at an average price of $273.87, for a total transaction of $903,771.00. Following the sale, the director now owns 339,879 shares in the company, valued at $93,082,661.73. The disclosure for this sale can be found here. Insiders have sold a total of 49,247 shares of company stock worth $15,204,166 over the last 90 days. Corporate insiders own 0.54% of the company’s stock.
WARNING: This article was published by Stock Observer and is the property of of Stock Observer. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.thestockobserver.com/2019/02/10/ls-investment-advisors-llc-lowers-holdings-in-illumina-inc-ilmn.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
See Also: Should You Consider an Index Fund?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.